To analyze the incidence, characteristics and risk factors of hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning (allo-RIC), we conducted a retrospective study in three Spanish centers. We analyzed 452 consecutive patients receiving allo-RIC. Of these, 92 patients (20%) developed marked hyperbilirubinemia (44 mg/day or 468.4 mM) after allo-RIC. The main causes of marked hyperbilirubinemia after transplant were cholestasis due to GVHD or sepsis (n ¼ 57, 62%) and drug-induced cholestasis (n ¼ 13, 14%). A total of 22 patients with marked hyperbilirubinemia (24%) underwent liver biopsy. The most frequent histological finding was iron overload alone (n ¼ 6) or in combination with other features (n ¼ 6). In multivariate analysis, the risk factors for marked hyperbilirubinemia after allo-RIC were non-HLAidentical sibling donors (hazard ratio (HR) 2.2 (95% confidence interval (CI) 1.4 --3.6) P ¼ 0.001), female donors to male recipients (HR 2.1 (95% CI 1.3 --3.3) P ¼ 0.003) and high levels of bilirubin and g-glutamyl transpeptidase before transplant (HR 4.5 (95% CI 2.5 --8.4) Po0.001 and HR 4.6 (95% CI 2.6 --8.1) Po0.001, respectively). Patients with marked hyperbilirubinemia showed higher 4-year nonrelapse mortality (HR 1.3 (95% CI 1 --1.7), P ¼ 0.02) and lower 4-year OS (HR 1.4 (95%CI 1.3 --1.7), Po0.001) than patients without. In conclusion, we confirm that marked hyperbilirubinemia is frequent and diverse after allo-RIC. Development of marked hyperbilirubinemia after allo-RIC is associated with worse outcome of the procedure.
INTRODUCTION
Liver function test abnormalities are commonly observed after allo-SCT. The severity of these abnormalities may range from mild and transient cholestasis due to pharmacological toxicity to severe and lethal hepatic failure related to acute GVHD (aGVHD). Cholangitis lenta due to sepsis, veno-occlusive disease (VOD), iron overload and base-line disease liver involvement appear as other causes of liver injury after SCT. 1 --5 Because some of these situations often coexist at the same time point and liver biopsies are not routinely performed in this population of patients (mainly because of thrombocytopenia and/or unstable medical condition of many patients), the diagnosis of liver injury after allo-SCT is commonly difficult. 5, 6 Reduced-intensity conditioning (RIC) regimens are known to be less toxic than conventional myeloablative conditionings and have made performing allo-SCT possible in patients who, otherwise, would not have been considered eligible for transplantation. However, as RIC allo-SCT (allo-RIC) is usually performed in elderly, unfit or heavily pretreated patients, organ toxicities are still frequent and may limit its use. 7 --9 Despite these concerns, very few studies regarding liver function after transplantation have been conducted in the RIC setting. 1, 2 With an attempt to reach a better understanding of liver injury in the allo-RIC setting, we conducted a study in a large population of allo-RIC recipients with a long follow-up receiving a highly homogeneous treatment. We focused on patients with hyperbilirubinemia (bilirubin 468.4 mM) after allo-RIC and tried to described its incidence, characteristics, risk factors and impact on transplant outcomes.
PATIENTS AND METHODS
The study included 452 consecutive adult patients who received an allo-RIC in three transplant centers in Spain (Hospital de la Santa Creu i Sant Pau, Barcelona, Hospital Clínic, Barcelona and Hospital Universitario, Salamanca) between February 1998 and November 2008. The transplant protocols were approved by national and local ethics committees, and patients gave written informed consent for their inclusion in each protocol.
Conditioning regimen, GVHD prophylaxis and supportive care management
The transplant protocol has been published elsewhere. 10, 11 In brief, the conditioning regimen included fludarabine (150 mg/m 2 ) in combination with melphalan (70 --140 mg/m 2 ; lymphoid malignancies and multiple myeloma) and BU (8 --10 mg/kg; myeloid malignancies, except for CML). Patients with CML and solid organ malignancies were excluded from the protocol and received fludarabine with low-dose TBI 2 Gy or CY, respectively. Despite the fact that some patients had received fludarabine in combination with oral BU at 10 mg/kg, pharmacokinetic dosage adjustment of BU was performed to ensure a similar steadystate concentration (range 800 --1000 ng/mL), 12 irrespective of the final dose administered. Patients receiving BU at 10 mg/kg showed similar outcomes than patients receiving 8 mg/kg, as published recently. 13 Thus, as all patients were exposed to a similar concentration of BU, we included in the current study such conditioning as a RIC regimen. GVHD prophylaxis included CsA plus MTX or CsA plus mycophenolate mofetil. CsA was started on day À7 at a dose adjusted to blood levels (between 200 and 300 ng/mL) determined by chemiluminescent microparticle immunoassay. MTX was administered on days þ 1, þ 3 and þ 6 (10 mg/m 2 , followed by folinic acid rescue). Mycophenolate mofetil was started on day 0 (at least 10 h after infusion of progenitors) at a dose of 15 mg/kg every 8 h and continued until day þ 30. In vivo T-cell depletion with antithymocyte globulin was used in patients receiving a transplant from HLA-mismatched related or unrelated donors.
Acyclovir, fluconazole and quinolones (ciprofloxacin or norfloxacin) were administered from day À1 and until neutrophil recovery as infectious prophylaxis. CMV infection screening (using antigenemia pp65 before 2003 and reverse transcriptase-PCR after that year) for guiding pre-emptive therapy was performed as described elsewhere in detail.
14 Galactomannan Platelia assay (Bio-Rad Laboratories, Marnes-La-Coquette, France) in blood samples was routinely performed since 2003. 15 No prophylactic ursodeoxycholic acid or any other agent to prevent liver injury was used in any of the centers during the study period.
Management of liver dysfunction
Pretransplant screening of liver function has been published 13 and included determinations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, alkaline phosphatase, g-glutamyl transpeptidase (GGT), albumin levels, total and conjugated bilirubin, international normalized ratio, hepatitis B surface antigen, hepatitis B core antibodies and antibodies against hepatitis C virus as well as imaging studies if necessary. High levels of AST, ALT, GGT and alkaline phosphatase liver tests were considered when 42.5 Â upper normal limit (UNL) and for bilirubin when 41.5 Â UNL. Abnormal international normalized ratio was considered when higher than UNL. Albumin levels were treated as continuous and dicotomic variables (cutoff point in the median level, 40 g/L).
AST, ALT, alkaline phosphatase, GGT, albumin levels and total and conjugated bilirubin were screened daily during hospitalization and at every visit during outpatient management. International normalized ratio was determined at least weekly during the first 3 months of follow-up. In case of liver test abnormalities, patients underwent imaging studies (ultrasonography or computed tomography scan) and microbiological studies (CMV antigenemia/PCR, blood cultures and other viral PCR studies, that is, adenovirus and human herpesvirus 6) according to the clinical presentation. If VOD was suspected, hepatic venous pressure gradient was performed. Liver biopsy was considered in patients with no clear cause of hepatic disease and with an acceptable estimated risk of developing severe complications.
Review of the data and diagnostic criteria of liver disease Medical charts were retrospectively reviewed by one investigator in each center. Patients with severe liver dysfunction were also reviewed by a hepatologist (IC-V). Bilirubin levels were given in the International System of Units. Patients presenting bilirubin peaks between 22 and 68.3 mM (1.3 --3.9 mg/dL) were considered to have mild bilirubin levels, whereas patients with bilirubin peaks 4119.7 mM (7 mg/dL) were considered to have very high bilirubin levels as described. 1 As mild bilirubin abnormalities (22 --68.3 mM) are very frequent, often transient and very difficult to characterize after allo-SCT, its clinical and pathological characteristics were not analyzed. Hyperbilirubinemia was considered in patients presenting maximal total serum bilirubin level of X68.4 mM (4 mg/dL) according to previous studies. 1, 2 For clarification purposes, the term hyperbilirubinemia in this manuscript refers to patients with marked elevation of bilirubin levels (44 mg/day or 468.4 mM), although by definition all patients with bilirubin levels above the UNL would have hyperbilirubinemia. Patients with previously known Gilbert's syndrome or hyperbilirubinemia due to hemolysis were excluded.
Regarding causes of hyperbilirubinemia, cholestasis was attributed to GVHD when the patient had histologically demonstrated GVHD in the liver or in another organ, or sepsis in those patients with clinical or analytical signs of active infection. As GVHD and infections are frequently presented at the same time in a particular patient, we decided to combine these abnormalities in a single entity as previously described.
2 Drug-induced cholestasis was considered in patients without evidence of GVHD or infection presenting hyperbilirubinemia during or shortly after conditioning regimen or within the first week after beginning of a recently introduced and well-characterized hepatotoxic drug. CsA-related hyperbilirubinemia was considered in (1) patients with blood levels above the upper limit of target range (300 ng/mL) who presented an improvement of hyperbilirubinemia after reduction of CsA dose or (2) patients with blood levels within the optimal range who lowered their bilirubinemia after discontinuation of the drug. Cholestasis due to viral infection was considered in those patients presenting CMV or other active hepatotropic viral infection (detected in the liver or in other organs) and those with microbiological or histological findings of viral infection in liver biopsy. VOD was diagnosed according to the Seattle criteria. 16 Regarding iron overload, patients were included in this category if they had one of the following: (1) liver biopsy or magnetic resonance imaging suggesting severe iron deposits or (2) high levels of serum ferritin, no other attributed causes of hyperbilirubiemia and improvement of bilirubin levels after chelation therapy or phlebotomies. Finally, when no agreement in the causes of hyperbilirubinemia was reached between the local reviewer and the central reviewer (hepatologist, IC-V), we included the event in the OTHERS category except for GVHD and sepsis (as explained). Despite its limitations and for clarification purposes, we attributed a single cause of hepatic disease to every hyperbilirubinemia event following the classification mentioned above, although other secondary causes might have contributed to the event. This strategy has been followed by other groups in their studies regarding liver dysfunction in the allo-SCT setting. 1, 2 Time to bilirubin peak was calculated from the day of hematopoietic cell infusion to the day of maximum peak of bilirubin levels. This information was only included for description purposes as comparisons between patients dying of or surviving from the hyperbilirubin event might be impaired with this indicator.
End points and statistical analysis
The primary end point of the study was to determine the impact of hyperbilirubinemia on the outcome of allo-SCT. Secondary end points were to classify and describe hepatic dysfunction after transplant, and to determine its frequency and risk factors.
OS was defined as being alive at latest follow-up and calculated from day 0 of the transplant. Nonrelapse mortality (NRM) was defined as the time from day 0 of the transplant to death from any cause but relapse. The incidences of hyperbilirubinemia, aGVHD, chronic GVHD, NRM and relapse were calculated using cumulative incidence estimates, taking into account the competing risk model. 17, 18 The development of hyperbilirubinemia and GVHD after SCT were treated as time-dependent covariates to evaluate their impact on the outcome of allo-SCT. Patients dying before engraftment and before day þ 100 were not considered for aGVHD and chronic GVHD analysis, respectively. The probability of OS was estimated from the time of transplantation using Kaplan --Meier curves 19 and compared using the log-rank test. Comparison of characteristics between the causes of hyperbilirubinemia was performed using 2 Â 2 tables made using w 2 or Fisher's exact t-tests for dichotomic variables and t-test for continuous variables. Univariate Cox regression model was used to estimate risk factors for hyperbilirubinemia. The multivariate analysis (MVA) was performed taking into account the competing risk structure with relapse being a competitive event for NRM, the development of hyperbilirubinemia, VOD, aGVHD and chronic GVHD. Pretransplant variables with a significance level of Pp0.1 in the univariate analysis were included in the MVA where a significance level of Pp0.05 was required.
All statistical analyses were performed using SPSS, version 17.0 (SPSS, Chicago, IL, USA), with the exception of the cumulative incidence analyses, which were carried out with NCSS 2004 (Number Cruncher Statistical System, Kaysville, UT, USA).
RESULTS

Patient characteristics
Pretransplant patient characteristics are summarized in Table 1 and did not differ between centers. Median follow-up for survivors was 52 months (range 3 --123).
Causes of hyperbilirubinemia Bilirubin levels above the UNL were found after allo-RIC in 360 patients (80%). In all, 268 patients (59%) presented mild hyperbilirubinemia (22 --68.3 mM). A total of 92 patients (20%) developed hyperbilirubinemia after allo-SCT for a 4-year cumulative incidence of 21% (95% confidence interval (CI) 19 --23). Median time to bilirubin peak after allo-RIC was 96 days (range 0 --1251). Cholestasis due to GVHD or sepsis was found in 57 patients (62%), drug-induced cholestasis in 13 (14%), cholestasis due to viral infection in 5 (5%; 4 CMV and 1 EBV reactivations) and VOD in 4 patients (4%; Table 2 ). A total of 13 (14%) patients presented other causes of hyperbilirubinemia. Severe liver injury due to iron overload and hepatic involvement of baseline hematological disease (non-Hodgkin's lymphoma) were found in 3 (3%) patients each. The remaining patients presented immune hepatitis (1), hepatic involvement of post transplant lymphoproliferative disorder (1) and liver injury of unknown origin (1). Four (4%) patients were included in the unknown category as it was not possible to determine a cause of liver disease despite all diagnostic examinations. Liver biopsy in three out of these four patients revealed only mild iron overload, which was not considered to be the cause of hyperbilirubinemia by the investigators.
Regarding the time of onset and intensity of bilirubin peak, patients with cholestasis due to GVHD or sepsis seemed to show later peak median of 109 days (range 9 --1220) vs 26 days (range 1 --455) and reached a higher bilirubin peak median of 150.5 mM (range 73.5 --1149) vs 85.5 mM (range 68.4 --292.4, P ¼ 0.04) than patients with drug-induced cholestasis.
Regarding VOD, 4 (4%) patients with hyperbilirubinemia and 6 patients in the whole cohort (1.3%) met the diagnostic criteria at a median of 15 days (range 2 --28). Conditioning regimen consisted of fludarabine and melphalan in three and fludarabine and BU in three patients. Four of the six patients presenting VOD had undergone previous autologous transplantation.
A total of 23 biopsy samples from 22 patients with hyperbilirubinemia (24%) were available (19 liver biopsies and 4 necropsies). A definitive histopathological diagnosis was obtained in 22 samples (96%). In one patient, insufficient liver tissue to make a clear diagnosis was obtained. The details of histopathological findings and diagnostic procedures are summarized in Table 3 . No severe biopsy-related adverse events occurred in patients undergoing liver biopsy. Outcome NRM. A total of 132 patients (29%) experienced NRM at median follow-up. Cumulative incidence of 4-year NRM was 30% (95% CI 26 --35). The most common causes of NRM were GVHD and infections (51 patients died from GVHD with infection, 45 from infection without GVHD and 27 from GVHD without infection). Other causes of NRM included renal microangiopathy (n ¼ 2), stroke (n ¼ 2) and suicide (n ¼ 1).
Four patients died because of severe hepatic disease not related to GVHD or infections. Among them, two patients died because of VOD, one because of toxic hepatitis related to CY-based conditioning and one because of unexplained severe hepatic failure before engraftment (necropsy was not performed).
In the MVA, patients presenting hyperbilirubinemia had higher 4-year NRM than patients without hyperbilirubinemia (hazard ratio (HR) 1.3 (95% CI 1 --1.7) for a cumulative incidence of 78% (95% CI 73 --83) vs 22% (95% CI 19 --25), P ¼ 0.02; Figure 1 ). Other variables associated with higher 4-year NRM in the MVA were non-HLA-identical sibling donors (HR 2.3 (95% CI 1.5 --3.5), Po0.001), female donors to male recipients (HR 1.7 (95% CI 1.1 --2.4), P ¼ 0.01), patients 460 years of age (HR 1.9 (95% CI 1.2 --2.9), P ¼ 0.005), the development of grade II --IV acute GVHD (HR 1.8 (95% CI 1.3 --2.6), Po0.001) and VOD (HR 2.9 (95% CI 1.1 --6.6), P ¼ 0.02). Baseline disease, conditioning regimen, GVHD prophylaxis, advanced disease status at SCT, use of T-cell depletion in the conditioning regimen and stem cell source did not have an impact on NRM or OS in the MVA. Patients with mild hyperbilirubinemia (22 --68.3 mM) also showed higher 4-year NRM than patients without bilirubin abnormalities (HR 2.5 (95% CI 1.5 --4.4), P ¼ 0.001).
OS and relapse. At median follow-up, a total of 216 (48%) patients were alive for a probability of 4-year OS of 47% (95% CI 45 --50). In the MVA, patients with hyperbilirubinemia (X68.4 mM) had a lower 4-year OS than patients without (o68.4 mM); HR 1.4 (95% CI 1.3 --1.7) for a probability of 18% (95% CI 12 --22) vs 58% (95% CI 54 --61), Po0.001; Figure 1 ). Other risk factors for lower OS were non-HLA-identical sibling donors (HR 1.8 (95% CI 1.3 --2.5), P ¼ 0.001), patients 460 years of age (HR 1.6 (95% CI 1.1 --2.2), P ¼ 0.006) female donors to male recipients (HR 1.4 (95% CI 1 --1.8), P ¼ 0.04) and the development of grade II --IV aGVHD (HR 1.5 (95% CI 1.3 --1.9), Po0.001). Patients with mild bilirubin abnormalities (22 --68.3 mM) also showed lower 4-year OS than patients with normal bilirubin levels (o22 mM) during follow-up (HR 1.6 (95% CI 1.2 --2.3), P ¼ 0.005).
Globally, 151 (33%) patients experienced relapse of the underlying disease, for a cumulative incidence of 33% (95% CI 29 --37). Only predominant histopathological finding/s in every specimens. GVHD was diagnosed in 7 patients including 1 patient with cholestasis, 2 patients with centrizonal hepatocyte necrosis and 4 patients with mixed portal inflammation as the main histopathological finding. Patients with and without hyperbilirubinemia after allo-SCT had similar risk of relapse (HR 1.3 (95% CI 0.8 --1.9), P ¼ 0.3).
Risk factors for hyperbilirubinemia Risk factors for the development of hyperbilirubinemia are summarized in Table 4 . In the MVA, male patients with female donors, non-HLA-identical sibling donors and those with high GGT and bilirubin levels before allo-SCT had a higher risk of hyperbilirubinemia after transplantation. Among the 92 patients with hyperbilirubinemia, 35 (38%) patients were considered to have baseline liver disease at transplant. Most frequent baseline liver diseases were isolated GGT/alkaline phosphatase elevations (n ¼ 14, 15%), alcoholic fatty liver or hepatitis (n ¼ 5, 5%) and nonalcoholic steatohepatitis (n ¼ 5, 5%). Less frequent liver diseases included drug-induced liver toxicity (n ¼ 4, 4%), compensated cirrhosis (n ¼ 4, 4%) and isolated AST/ALT elevations (n ¼ 3, 3%). Disease definitions and details on pretransplant liver disease have been recently published. 13 
DISCUSSION
Our study confirms that hyperbilirubinemia is a frequent and severe complication after allo-RIC with major impact on transplant outcomes. Both transplant and patient characteristics seem to play a role on the development of hyperbilirubinemia after transplantation and, thus, hyperbilirubinemia might simply be a surrogate marker for a combination of other high-risk features.
The cumulative incidence of hyperbilirubinemia in our study was 21%, similar to other studies conducted in the allo-RIC setting with the same diagnostic criteria.
1,2 The incidence of hepatic dysfunction after allo-SCT varies greatly according to the study definition used. Hence, one large study 20 reported incidences of 1.4% when only extremely high levels of transaminases (AST41500U/L) were considered for diagnosis, whereas others with less strict criteria found higher incidences 21, 22 (70 --90%). We followed the criteria established by Hogan et al. 1 as it is one of the first, more reproduced and most consistent reports on hepatic dysfunction after allo-RIC. However, greater efforts are warranted to establish consensus and homogeneous diagnostic criteria to be used in clinical studies by all investigators. As the NCI (National Cancer Institute) common toxicity criteria are widely used and accepted by clinicians over the world, 23 we think that these could be an optimal starting point for expert discussion.
Cholestasis due to GVHD or sepsis was the most frequent cause of hyperbilirubinemia in our population. In clinical practice, a distinction between these two entities is usually difficult as they often coexist at the same time. In addition, the intensive immunosuppressive therapy used to treat GVHD might worsen underlying infections. We support diagnostic efforts to distinguish these two entities. Liver biopsy is a very valuable diagnostic tool, particularly in cases with overlapping clinical features, but it is an invasive procedure with significant complications. 6 However, in our series, liver biopsy allowed a definitive histopathological diagnosis in 96% of the patients without any severe complication. Another study conducted in SCT recipients 5 reported very similar results with 92% of diagnostic biopsies and only one severe adverse event with no biopsy-related mortality. However, a selection bias surely occurred in these studies, as only patients with mild or moderate estimated risk of biopsy-related complications had been considered for liver biopsy.
Less frequent causes of hyperbilirubinemia in our series included VOD and iron overload. Only six patients in the whole cohort (1.3%) met the criteria for VOD, which represented the main cause of hyperbilirubinemia in 4% of the patients. These results confirm the low incidence of VOD reported in allo-RIC recipients. The intensity of the conditioning regimen seems to play a key role in the development of VOD. Hence, in allo-RIC recipients, despite older age and greater comorbidities, 24, 25 reported incidences of VOD range from 0 to 7%, 1, 26, 27 whereas in the myeloablative setting the reported incidence is B10--15%. 28 --30 On the other hand, iron overload was found in 55% of liver biopsies, although it was considered the main cause of hyperbilirubinemia in only 3 (14%) of the patients undergoing liver biopsy. Ours findings and those of others 5 suggest that liver iron overload is more common than traditionally considered by clinicians. However, the precise impact of iron overload on transplant outcomes and the best way to determine it are still an issue of debate in the allo-RIC setting. 31 The development of hyperbilirubinemia had a profound impact on mortality and survival in our patients as described by others. 32 Nevertheless, continuous improvements in transplant outcomes may not allow direct comparisons between ours and other studies conducted in different time points and patient populations. The impact of hyperbilirubinemia on the outcome persisted when the development of aGVHD was included in the statistical model. Hence, it seems that aGVHD might only be partially responsible for the impact of hyperbilirubinemia on the outcome of allo-RIC. Other patient-related (age, previous chemotherapy toxicity) and non-GVHD transplant-related characteristics (infections, VOD) might contribute to the worse outcome of patients developing hyperbilirubinemia, which would act as a surrogate marker for several of these conditions. Interestingly, OS and NRM were worse in patients with mild hyperbilirubinemia (22 --68.3 mM) than in patients without bilirubin abnormalities (o22 mM). These finding would support an early and aggressive approach to diagnosis and treatment when mild bilirubin abnormalities appear after allo-SCT. However, the impact of mild bilirubin abnormalities after allo-RIC have to be further studied as others 1 did not confirmed our findings.
Patients with liver test abnormalities before allo-RIC (high GGT and bilirubin levels) seemed more likely to develop hyperbilirubinemia after transplantation. Our group 13 and others 33 have analyzed the impact of pretransplant liver function abnormalities in the allo-SCT setting, showing the deleterious effect of liver injury on several outcomes. Other risk factors for hyperbilirubinemia in our patients were female donors to male recipients and donors other than HLA-identical siblings. Both of these variables have been identified as risk factors for GVHD, 34 the main cause of hyperbilirubinemia in our patients. Furthermore, patients with GVHD have a high risk of infection and need for longer immunosuppressive therapy, 35 which were other causes of hyperbilirubinemia in our series.
Interestingly, the use of BU did not seem to have an impact on the development of hyperbilirubinemia or VOD after transplantation. BU is an alkylating agent with hepatotoxic effects and has been associated with a higher risk of VOD. 36 Its hepatic toxicity is known to be dose dependent and it appears to be more frequent and severe in patients with higher-dose exposure. 37 Furthermore, the hepatotoxic effects of BU seem to be higher in patients receiving TBI or CY. The physiopathological mechanism of BU toxicity is not completely understood. One plausible explanation is that BU increases the susceptibility of hepatocytes to other drugs by reducing the intracellular glutathione levels. Glutathione is the most abundant intracellular antioxidant and is required to conjugate chemicals. Hence, hepatocytes would be more susceptible to injury caused by other drugs following BU administration. 38 Indirect evidence supporting this hypothesis comes from the studies suggesting a lower risk of sinusoidal injury when BU is given last in order in the BU/CY regimen. 39 Several strategies have been developed in an attempt to reduce the impact of liver dysfunction on mortality after SCT, including the use of danaparoid, defibrotide and N-acetylcysteine. The results of these studies focused especially in VOD and showed great disparity of results. 40 --42 The most widely spread strategy to prevent cholestatic liver disease is the use of ursodeoxycholic acid during the early months of the transplant. A randomized prospective clinical trial in adult patients receiving myeloablative conditioning found that SCT recipients treated with ursodeoxycholic acid during the early phase after transplantation had lower risk of liver injury, aGVHD and NRM than patients not receiving ursodeoxycholic acid. 43 However, another randomized study did not find any survival benefit of the combination of heparin and ursodeoxycholic acid compared with heparin alone. 44 More recently, a meta-analysis including 824 patients from 6 studies showed a lower risk of VOD and NRM in patients receiving ursodeoxycholic acid. The analysis did not show a survival benefit for the use of ursodiol. Moreover, the pooled results of the two randomized studies showed a nonsignificant trend to a lower OS in the ursodiol group. 45 Remarkably, all these studies were conducted in the myeloablative setting. To our knowledge, no studies have demonstrated a benefit in terms of survival and NRM of ursodeoxycholic acid in the allo-RIC setting. Despite the fact that our patients did not receive ursodeoxycholic acid, we consider that the results of the current study are applicable in the current practice in the RIC setting, at least until consistent evidence favoring the use of ursodeoxycholic acid in allo-RIC recipients appears.
In conclusion, we confirm that hyperbilirubinemia (bilirubin 468.4 mM) is common after allo-RIC and it is associated with worse outcome of the procedure. Improvement in the diagnostic, prophylactic and therapeutic measures could, thus, contribute to ameliorate transplantation outcomes in the allo-SCT setting.
